Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression
Authors:
- 1 June 2020
- journal article
- research article
- Published by Elsevier in International Immunopharmacology
- Vol. 83, 106478
Abstract
No abstract availableKeywords
Funding Information
- Taishan Scholars Project (tsqn201812149)
- Academic promotion programme of Shandong First Medical University
This publication has 37 references indexed in Scilit:
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- The future of immune checkpoint therapyScience, 2015
- Robust enumeration of cell subsets from tissue expression profilesNature Methods, 2015
- Non-small-cell lung cancers: a heterogeneous set of diseasesNature Reviews Cancer, 2014
- Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung CancerPLOS ONE, 2013
- Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive ImmunityCancer Immunology Research, 2013
- GSVA: gene set variation analysis for microarray and RNA-Seq dataBMC Bioinformatics, 2013
- X-TileClinical Cancer Research, 2004